|
Adverse event
|
Any grade
|
Grades 1–2
|
Grade 3
|
Grade 4
|
|---|
|
Thrombocytopenia, n (%)
|
16 (50.0%)
|
9 (28.1%)
|
4 (12.5%)
|
3 (9.4%)
|
|
Hypertension, n (%)
|
14 (43.8%)
|
5 (15.6%)
|
9 (28.1%)
|
0
|
|
Neutropenia, n (%)
|
12 (37.5%)
|
7 (21.9%)
|
4 (12.5%)
|
1 (3.1%)
|
|
Leukopenia, n (%)
|
11 (34.4%)
|
11 (34.4%)
|
0
|
0
|
|
Anorexia, n (%)
|
10 (31.4%)
|
7 (21.9%)
|
3 (9.4%)
|
0
|
|
Proteinuria, n (%)
|
9 (28.1%)
|
8 (25.0%)
|
1 (3.1%)
|
0
|
|
Anemia, n (%)
|
8 (25.0%)
|
8 (25.0%)
|
0
|
0
|
|
Fatigue, n (%)
|
7 (21.9%)
|
4 (12.5%)
|
3 (9.4%)
|
0
|
|
Oral mucositis, n (%)
|
6 (18.8%)
|
6 (18.8%)
|
0
|
0
|
|
Vomiting, n (%)
|
5 (15.6%)
|
5 (15.6%)
|
0
|
0
|
|
Hand-foot syndrome, n (%)
|
2 (6.3%)
|
1(3.1%)
|
1 (3.1%)
|
0
|
|
Elevation of ALT/AST, n (%)
|
2 (6.3%)
|
2 (6.3%)
|
0
|
0
|
|
Tumor bleeding, n (%)
|
1 (3.1%)
|
0
|
0
|
1 (3.1%)
|
- ALT alanine aminotransferase, AST aspartate aminotransferase. Any grade adverse events occurring in > 5% of patients and all grade 3 or 4 adverse events were listed. No grade 5 adverse events occurred
